Cargando…

Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention

Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is char...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hangkuan, Wang, Zhijia, Sun, Haonan, Teng, Tianming, Li, Yongle, Zhou, Xin, Yang, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847976/
https://www.ncbi.nlm.nih.gov/pubmed/33537347
http://dx.doi.org/10.3389/fcvm.2020.599334
_version_ 1783645028511383552
author Liu, Hangkuan
Wang, Zhijia
Sun, Haonan
Teng, Tianming
Li, Yongle
Zhou, Xin
Yang, Qing
author_facet Liu, Hangkuan
Wang, Zhijia
Sun, Haonan
Teng, Tianming
Li, Yongle
Zhou, Xin
Yang, Qing
author_sort Liu, Hangkuan
collection PubMed
description Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is characterized by endothelial dysfunction, platelet activation, thrombosis, coagulopathy, and multiple organ failure. Globally, millions of patients with coronary heart disease undergo percutaneous coronary intervention (PCI) each year. These patients undergo high-intensity antithrombotic therapy during hospitalization and dual antiplatelet therapy (DAPT) for at least 6 months post PCI. COVID-19 is characterized by changes in platelet counts. Treatment of ischemic events that occur during stent implantation is associated with bleeding complications in patients following PCI complicated by COVID-19. This review summarizes recent progress in activation status and levels of COVID-19-related platelet changes. These findings will provide information on the effectiveness of antithrombotic therapy for the management of platelet changes in COVID-19 patients.
format Online
Article
Text
id pubmed-7847976
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78479762021-02-02 Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention Liu, Hangkuan Wang, Zhijia Sun, Haonan Teng, Tianming Li, Yongle Zhou, Xin Yang, Qing Front Cardiovasc Med Cardiovascular Medicine Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is characterized by endothelial dysfunction, platelet activation, thrombosis, coagulopathy, and multiple organ failure. Globally, millions of patients with coronary heart disease undergo percutaneous coronary intervention (PCI) each year. These patients undergo high-intensity antithrombotic therapy during hospitalization and dual antiplatelet therapy (DAPT) for at least 6 months post PCI. COVID-19 is characterized by changes in platelet counts. Treatment of ischemic events that occur during stent implantation is associated with bleeding complications in patients following PCI complicated by COVID-19. This review summarizes recent progress in activation status and levels of COVID-19-related platelet changes. These findings will provide information on the effectiveness of antithrombotic therapy for the management of platelet changes in COVID-19 patients. Frontiers Media S.A. 2021-01-18 /pmc/articles/PMC7847976/ /pubmed/33537347 http://dx.doi.org/10.3389/fcvm.2020.599334 Text en Copyright © 2021 Liu, Wang, Sun, Teng, Li, Zhou and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Liu, Hangkuan
Wang, Zhijia
Sun, Haonan
Teng, Tianming
Li, Yongle
Zhou, Xin
Yang, Qing
Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
title Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
title_full Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
title_fullStr Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
title_full_unstemmed Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
title_short Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
title_sort thrombosis and coagulopathy in covid-19: current understanding and implications for antithrombotic treatment in patients treated with percutaneous coronary intervention
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847976/
https://www.ncbi.nlm.nih.gov/pubmed/33537347
http://dx.doi.org/10.3389/fcvm.2020.599334
work_keys_str_mv AT liuhangkuan thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention
AT wangzhijia thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention
AT sunhaonan thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention
AT tengtianming thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention
AT liyongle thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention
AT zhouxin thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention
AT yangqing thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention